Norge - norsk - Statens legemiddelverk

astellas pharma a/s - takrolimus - konsentrat til infusjonsvæske, oppløsning - 5 mg/ ml

Norge - norsk - Statens legemiddelverk

teva sweden ab - takrolimus - kapsel, hard - 1 mg

Norge - norsk - Statens legemiddelverk

teva sweden ab - takrolimus - kapsel, hard - 0.5 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - macimorelin acetate - diagnostiske teknikker, endokrine - macimorelin - dette legemidlet er kun til diagnostisk bruk.  ghryvelin is indicated for the diagnosis of growth hormone deficiency (ghd) in adults.

Den europeiske union - norsk - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - karsinom, ikke-småcellet lunge - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Den europeiske union - norsk - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - cannabidiol - lennox gastaut syndrome; epilepsies, myoclonic - antiepileptics, - epidyolex er indikert for bruk som adjuvant behandling av anfall assosiert med lennox gastaut syndrom (lgs) eller dravet syndrom (ds), i forbindelse med clobazam, for pasienter fra 2 år og eldre.

Den europeiske union - norsk - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - leukemi, myeloid, akutt - antineoplastiske midler - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Den europeiske union - norsk - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitt, atopisk - andre dermatologiske preparater - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Den europeiske union - norsk - EMA (European Medicines Agency)

amgen europe bv - sotorasib - karsinom, ikke-småcellet lunge - antineoplastiske midler - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Den europeiske union - norsk - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.